Diagnostics & Precision Testing

The US Food and Drug Administration granted Breakthrough Device designation to Natera's multi cancer early detection blood test, a move that reshapes how investors frame the company's diagnostics pipeline. The designation follows a strong run in Natera's share price, with a 30-day return of 21.31%, a 90-day move of 48.44%, a year-to-date gain of 75.10%, and a 1-year total shareholder return of 136.73%. The stock's latest close of $400.71 sits above the most followed fair value estimate of $355.93, which implies the shares are 13% overvalued under a 7.5% discount rate. By contrast, the Simply Wall St discounted cash flow model estimates a future cash flow value of $599.47, suggesting the shares trade about 33% below that level. Natera's investment in new product launches such as Fetal Focus NIPT, Signatera Genome, and AI-based biomarkers, along with its R&D pipeline, positions it to capture growth from long-term trends in personalized medicine and early detection, though tighter reimbursement rules or sustained high R&D spending could pressure profitability.

On October 10, the AI-Empowered Precision Diagnosis and Treatment of Lung Cancer Summit Forum and the launch ceremony for the National Respiratory Medicine Center's Lung Cancer Precision Diagnosis and Treatment Standardization Project, hosted by the National Respiratory Medicine Center of the First Affiliated Hospital of Guangzhou Medical University and the Guangdong Provincial Chest Disease Society, and organized by KingMed Diagnostics, was held in Guangzhou. At the event, DeepGEM 2.0, a multimodal AI model for lung cancer pathology genomics jointly developed by the First Affiliated Hospital of Guangzhou Medical University and KingMed Diagnostics, was officially released. A multicenter research project involving 50 medical institutions nationwide was also launched, marking the model's formal entry into large-scale clinical validation. According to Dr. Liu Si, head of KingMed Diagnostics' artificial intelligence division, DeepGEM 2.0 analyzes routine digital pathology slide images without requiring additional sampling and can deliver results in as little as one minute. Building on the original six genes—EGFR, KRAS, ALK, ROS1, TP53, and LRP1B—it adds BRAF, ERBB2, FGFR, MET, NTRK, and RET, bringing the total to 12 genes and achieving full coverage of genes corresponding to approved targeted therapies for lung cancer in China. The model will subsequently be deployed in a lightweight form at more than 500 medical institutions. Using an approach of AI-based initial screening combined with targeted validation of specific genes, it is expected to reduce the cost of lung cancer genetic testing to the range of several hundred yuan. Zhong Nanshan, an academician of the Chinese Academy of Engineering and director of the Guangzhou National Laboratory, said that in the new AI era, scientific research must aim high while serving the people. In 2025, the First Affiliated Hospital of Guangzhou Medical University, together with KingMed Diagnostics and Tencent, released DeepGEM, a multimodal pathology genomics model capable of identifying genes from images. After nearly a year of multicenter data validation and clinical refinement, and iterative optimization using nearly 8,000 digital pathology slides from 31 provinces across China provided by KingMed Diagnostics, it has been upgraded to version 2.0. Liang Yaoming, chairman and CEO of KingMed Diagnostics, said that AI pathology technology brings new opportunities to narrow regional disparities in diagnosis and treatment and to reduce costs while improving efficiency. KingMed Diagnostics will leverage the network advantages of its nationwide intelligent medical diagnostic service platform to bring innovative pathology AI technology to primary-level healthcare.

GE HealthCare announced a definitive agreement on October 5 to acquire Sofie Biosciences for $945 million in cash, with closing expected in the first half of 2027. The deal builds on an exclusive licensing agreement struck in October 2023 covering development and commercialization of Fluorine-18 FAPI-74 outside the United States and global rights to Gallium-68 FAPI-46, and it would add U.S. rights to F-18 FAPI-74 while expanding GE HealthCare's domestic radiopharmaceutical manufacturing network. The company also recently received CE Mark approval for its Photonova Spectra photon-counting CT scanner, its third clearance across key geographies in five months. In the second quarter of fiscal 2026, adjusted EBIT margin fell 40 basis points year over year to 14.2%, though diluted EPS rose 16.5%, a figure that included a one-time $129 million tariff refund under the International Emergency Economic Powers Act. After $2.3 billion of strategic acquisitions in the first half, GE HealthCare reported $10.1 billion in total debt and $2.1 billion in cash and equivalents at quarter-end.

Profound Medical Corp. and Telix Pharmaceuticals Limited have entered into a co-education agreement to advance PSMA-informed prostate care, the companies announced on October 9, 2026. The agreement establishes a framework to educate urologists, radiologists, nuclear medicine physicians and prostate cancer centers on the complementary roles of Telix's PSMA-targeting PET molecular imaging technologies, Gozellix and Illuccix, and Profound's MRI-guided, AI-powered, robotically-driven and incisionless TULSA-PRO platform across the prostate care continuum. Planned initiatives include participation in major scientific and medical society meetings, key opinion leader programs, educational summits, speaker programs and webinars, along with educational content, clinical case studies and best-practice materials. Profound said the collaboration increases its access to urologists across the U.S. and internationally through a strong strategic partner, and that it is also developing PSMA-PET-MR image-fusion capabilities for a planned future release of its Treatment Delivery Console software. Profound CEO and Chairman Arun Menawat said the agreement supports broader market development and could strengthen the clinical and economic value proposition of TULSA-PRO centers, while Telix Precision Medicine CEO Kevin Richardson said the collaboration aims to increase awareness of the complementary roles of PSMA-PET imaging and MRI-guided therapy.

Tasly announced that its wholly-owned subsidiary Tianjin Tasly Pride Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Indocyanine Green for Injection approved and issued by the National Medical Products Administration. Indocyanine Green for Injection is clinically used to diagnose various liver diseases such as cirrhosis, hepatic fibrosis, chronic hepatitis, and occupational and drug-induced toxic liver disease, and to assess the degree of liver damage and its reserve function. The drug can also be used for choroidal angiography to determine the location of choroidal disorders.

Adaptive Biotechnologies' modeled fair value per share has been lifted from US$26.36 to US$28.31, reflecting analyst optimism around the clonoSEQ minimal residual disease franchise. Multiple firms have raised their fair value estimates in recent months, including TD Cowen, BTIG, Piper Sandler and Guggenheim, with Guggenheim most recently at US$32 and Goldman Sachs at US$35. Goldman Sachs sees Adaptive Biotechnologies as a leader in next generation sequencing minimal residual disease testing, with current penetration at about 13% of the potential patient population. On the bearish side, Craig Hallum has flagged possible confusion around the proposed 2027 Centers for Medicare and Medicaid Services clinical laboratory fee schedule, since some billing codes used by the company are among those facing proposed cuts of up to 15%, though the firm does not expect a significant direct financial impact. In the updated model, revenue growth has adjusted from 16.84% to 16.03%, net profit margin from 3.77% to 3.95%, future P/E from 328.9x to 344.6x, and the discount rate from 8.23% to 8.24%.

Guardant Health announced that Guardant360 CDx has received CE-marking under Europe's In Vitro Diagnostic Medical Devices Regulation as a companion diagnostic for AstraZeneca's ETCAMAH, also known as camizestrant, in advanced ER-positive breast cancer. The test identifies patients with estrogen receptor-positive, HER2-negative locally advanced or metastatic breast cancer who may benefit from the next-generation oral selective estrogen receptor degrader and complete ER antagonist. Using a simple blood draw, clinicians can test for ESR1 mutations ahead of disease progression, and the European approval follows prior regulatory approvals of Guardant360 CDx as a companion diagnostic for ETCAMAH in the United States and Japan. The clearance marks the third companion diagnostic approval for ETCAMAH and the 31st companion diagnostic approval for Guardant Health. Chairman and co-CEO Helmy Eltoukhy said the company sees tremendous potential for this testing protocol to transform the treatment of other cancer types.

RadNet posted the strongest quarter among the five testing and diagnostics services stocks tracked, reporting revenues of $622.7 million, up 25% year on year and 2.3% above analysts' expectations, with a beat on EPS estimates. Dr. Howard Berger, President and Chief Executive Officer of RadNet, said the Imaging Center and Digital Health reportable operating segments continued to demonstrate strong growth and achieve record quarterly results, with Total Company Revenue up 25.0% and Digital Health segment Revenue up 56.5% from last year's same quarter. As a group, the five testing and diagnostics services stocks tracked beat analysts' consensus estimates by 2.8%, and their share prices are up 7.2% on average since the latest earnings results. Quest Diagnostics reported revenues of $3.04 billion, up 10.2% year on year and 2.3% above expectations, while Guardant Health reported revenues of $335 million, up 44.3% year on year and 6.4% above expectations, scoring the biggest analyst estimate beat, fastest revenue growth, and highest full-year guidance raise of the whole group. Labcorp delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update among its peers, with revenues of $3.73 billion, up 5.8% year on year and in line with analysts' expectations, while NeoGenomics reported revenues of $201.7 million, up 11.2% year on year and 2.2% above expectations.

Myriad Genetics and SOPHiA GENETICS announced a collaboration to advance new prostate cancer-specific genomic instability score technology, known as PrGIS, with AstraZeneca. PrGIS is a novel biomarker signature designed to assess chromosomal instability associated with homologous recombination deficiency in prostate cancer patients, and Myriad's proprietary MyChoice CDx test, currently available as a companion diagnostic in ovarian cancer, will produce the PrGIS score and is being advanced for prostate cancer as a new indication. As part of the collaboration, SOPHiA GENETICS is developing its solid tumor application for Extended Homologous Recombination Solution into a decentralized companion diagnostic solution that will incorporate Myriad's PrGIS technology, drawing on a cloud-based platform with more than 1,000 connected institutions in over 75 countries. Myriad also plans to present PrGIS research co-authored with AstraZeneca at the European Society for Medical Oncology Congress 2026, with full data available after the ESMO embargo period.

Avricore Health Inc. announced that its wholly owned subsidiary HealthTab Ltd. has completed an integration with HeartEye, a UK provider of AI-based retinal cardiovascular risk assessment, creating a new referral pathway into community pharmacy. Under the pathway, people found to be at elevated cardiovascular risk by a HeartEye retinal scan at their optician can be referred to a nearby HealthTab-enabled pharmacy for further assessment and care. HeartEye's Dr.Noon CVD test, developed by Mediwhale, uses AI to estimate cardiovascular risk from a retinal scan taken during a routine optician visit; when a patient is flagged at elevated risk, their Dr.Noon report QR code can be scanned into HealthTab at a nearby pharmacy, where a pharmacist carries out a point-of-care cholesterol test that feeds an automatic QRISK3 calculation, with all results displayed together on the patient's HealthTab dashboard. With newly qualified pharmacists in England registering as independent prescribers from September 2026, the pathway has the potential to take patients from identification and assessment through to treatment, where appropriate, within the community, supporting all three of the NHS 10 Year Health Plan's major shifts. HealthTab and Abbott will showcase their turnkey pharmacy-based point-of-care testing solution, including the new HeartEye integration, at The Pharmacy Show 2026 on October 11-12 at the NEC in Birmingham.

Oriental Ocean announced that its subsidiary, Mass Spectrometry Biotechnology Co., Ltd., has recently obtained a medical device registration certificate from the Shandong Provincial Medical Products Administration for its independently developed water-soluble vitamin assay kit using liquid chromatography-tandem mass spectrometry. The product is intended for in vitro quantitative determination of vitamins B1, B2, B3, B5, B6, B7, and B9 in human serum, further enriching the subsidiary's product line in the clinical testing field. The company cautioned that the product has not yet entered production after obtaining the certificate, and actual sales will be affected by multiple factors including market expansion efforts and demand, so the impact on performance remains uncertain.

Lifotronic Technology announced on October 8 that it has recently received notification from the U.S. Food and Drug Administration that its H100Plus hemoglobin testing system has obtained FDA 510(k) clearance. The product is intended for in vitro quantitative determination of glycated hemoglobin (HbA1c) in human whole blood, which can assist in the diagnosis of diabetes. The company stated that obtaining FDA clearance demonstrates that the product meets the relevant requirements of the U.S. Food and Drug Administration and is qualified to enter the U.S. market. In the first half of 2026, Lifotronic Technology achieved revenue of 604 million yuan and net profit attributable to the parent company of 79.27 million yuan.

Bangkok Genomics Innovation Public Company Limited, or BKGI, reported first-half 2026 results with net profit of 62.05 million baht, up 49.65 million baht, or 400%, from net profit of 12.40 million baht in the same period a year earlier. Total revenue came to 309.39 million baht, up 157.02 million baht, or 103%, from total revenue of 152.37 million baht in the same period last year. Dr. Saowalak Dansakul, Chief Executive Officer of BKGI, said the company is transitioning from a provider of NIFTY testing services to a full-service health and genomics innovation provider through three business models: instrument placement with reagent purchases, instrument purchases with reagent purchases, and instrument leasing with reagent purchases. It is also expanding its Precision Oncology portfolio with the OncoPRESS service and BRCA 1/2 testing, which are already partially reimbursed by the National Health Security Office. On revenue structure, the share from instrument and reagent sales rose to 55%, above the 45% from services, with reagent sales, which are recurring revenue, accounting for 36% of total revenue, or about 110 million baht, and the company expects to begin recognising significant revenue from reagent use starting in the third quarter of 2026. The ATMP group has begun contributing about 40.4 million baht in revenue and will become a driver of continuous reagent sales from 2027 onward. The company is also studying the feasibility of producing reagents in Thailand to manage supply chain and logistics risks, and expects second-half 2026 operating results to grow from the first half, supported by Oncology, Wellness & Longevity, NGS and ATMP, as well as the government-backed Phase 2 of the Genomics Thailand project.

Tempus announced an expanded, multi-year collaboration with Moderna and Merck to support the potential commercialization of intismeran autogene, also known as V940 or mRNA-4157, a potential first-in-class individualized neoantigen therapy being evaluated in combination with KEYTRUDA in patients with completely resected stage IIB-IV melanoma and other cancer types. Intismeran autogene is jointly developed by Moderna and Merck, known as MSD outside the United States and Canada, and the new collaboration builds on joint efforts initiated last year. Under the agreement, Tempus will manage the timely collection and transfer of tumor tissue and blood samples required for next-generation sequencing, and, subject to applicable regulatory approvals, will also provide NGS services to support the intismeran autogene design and manufacturing process. Financial terms of the collaboration were not disclosed. Moderna Chief Business Officer Said Francis said the partnership lets the company leverage Tempus's commercial footprint and advanced sequencing capabilities, while Jannie Oosthuizen, President of Global Oncology and MSD International, said such collaborations are helping build the infrastructure needed to bring individualized neoantigen therapies to patients at scale.

Roche Diagnostics has provided two molecular testing instruments to the Institut National de Santé Publique to support Ebola testing capacity in the Democratic Republic of Congo, where an outbreak caused by Bundibugyo virus has pushed demand for testing beyond current laboratory capacity. Roche will preconfigure the Light cycler and Magna Pure instruments and train local laboratory technicians before deploying the equipment to Bunia for validation testing. The Institut National de Santé Publique will conduct local validation of the Bundibugyo virus, after which Roche anticipates further tests could be shipped and additional instruments deployed. The delivery follows Roche's June announcement that it had developed a Research Use Only molecular PCR test targeting Bundibugyo virus. As of 28 September 2026, UN Health Authority data reported 8,067 confirmed cases and 3,901 deaths, a case fatality rate of 48.4% across 60 health zones in six provinces, and the WHO has assessed the risk in the DRC as very high and confirmed the outbreak remains a public health emergency of international concern.

NeoGenomics, Inc. issued preliminary third-quarter 2026 revenue guidance of about US$209 million with very strong next-generation sequencing growth and outlined plans to increase its full-year revenue guidance. The company also amended its bylaws to expand its Board to up to eleven directors. In a planned leadership transition, President and COO Warren Stone will become CEO and join the Board in January 2027, while current CEO Tony Zook moves to Executive Chair and the Board refreshes its independent leadership. The stronger revenue outlook, particularly in NGS, supports the near-term revenue catalyst but does not materially change the central risk that high fixed costs and heavy investment could weigh on margins if volumes soften or funding pressures persist. NeoGenomics' narrative projects $997.4 million revenue and $64.1 million earnings by 2029, with a $19.72 fair value estimate.

Oku Digital Health, Inc. announced its global launch from Topcon Healthcare, Inc., unveiling an AI-powered digital health company that turns routine eye exams into a front door for early disease detection and accelerated clinical development. The company operationalizes its Healthcare from the Eye approach across a connected network of more than 10,000 care locations, built on Topcon's global installed base of 50,000+ diagnostic devices, and says it has screened over 2.2 million patients outside of traditional eye care. Oku combines AI-supported diagnostics, EHR integration, and referral workflows to connect healthcare providers in primary care, optometry, ophthalmology, and specialties with pharmaceutical partners seeking patient data and real-world evidence for drug development and precision medicine. Ali Tafreshi, who remains Chief Strategy Officer for Topcon Corp.'s Eyecare Business Division and Chief Executive Officer of Topcon Healthcare Inc., leads Oku as Chief Executive Officer, joined by Chief Operating Officer Trent Norris, Chief Data AI Officer Matthew Lungren, Chief Medical Officer Daniela Ferrara, and Chief Strategy and Business Development Officer Jacques Gilbert. The company is built on Microsoft Azure cloud infrastructure and optimized for AI workloads with NVIDIA CUDA libraries, and will make its debut at the American Academy of Ophthalmology Annual Meeting in New Orleans from October 9 to 12, 2026, within the Topcon Healthcare booth at AAO 1737.

Telix Pharmaceuticals announced that the first patients in the United States have been dosed with Pixclara, its FDA-approved amino acid PET imaging drug for glioma, marking the start of U.S. commercial availability. The doses were administered at the Indiana University Health Neuroscience Center in Indianapolis and University Hospitals Cleveland Medical Center in Cleveland, with Telix's U.S. manufacturing and pharmacy distribution partner PharmaLogic Holdings Corp. supplying finished unit doses to the U.S. market. Pixclara, also known as floretyrosine F 18 or 18F-FET, is the only FDA-approved radiopharmaceutical imaging drug for glioma and is indicated to help differentiate recurrent or progressive glioma from treatment-related change in adults and pediatric patients one month of age and older. Gliomas account for approximately 30% of all brain and central nervous system tumors and 80% of all malignant brain tumors, with roughly 24,000 new glioma cases diagnosed in the U.S. each year. Telix said Pixclara is also the subject of a Phase 3 registrational study for potential indication expansion into the diagnosis of brain metastases.

Tempus AI has received 510(k) clearance from the U.S. Food and Drug Administration for Tempus ECG-MR, an AI tool for early mitral regurgitation detection. The clearance landed on top of a strong run in the shares, with a 1-day share price return of 9.03% lifting the latest quote to US$83.55 and building on a 30-day share price return of 29.29%, though the 1-year total shareholder return remains down 10.17%. The stock now trades above the average analyst target and above some intrinsic value estimates, with the most followed narrative anchoring fair value nearer $75.68, framing the latest close as roughly 10% overvalued. The company reported Q2 revenue growth of 22% year over year, with oncology testing volumes up 31% and Data Licensing and Modeling revenue up 36%, and it raised 2026 revenue guidance to around $1.6 billion while expecting approximately $65 million of Adjusted EBITDA. Risks to the story include a drag on profitability from the integration of Personalis and cooling expectations around AI products.

Safe Fertility Group Public Company Limited, or SAFE, disclosed that it is studying ways to expand cooperation with the National Health Security Office, or NHSO, on a project to screen for fetal chromosomal abnormalities from maternal blood, known as NIPT, in order to add revenue channels and extend its business, with clarity expected within next year. As for its operating performance trend in 2027, the company targets revenue growth of about 10-15% from 2026, when revenue is expected to be close to the previous year's 900 million baht, driven by expanding its business scope into genetic testing laboratories under Next Generation Genomic Company Limited, which provides testing services in reproductive medicine and maternal and child medicine to leading public and private healthcare facilities, as well as obstetrics and gynecology clinics both domestically and overseas. At present, SAFE's customer base is split roughly 50% Thai customers and 50% foreign customers, but in terms of revenue, about 60% comes from foreign customers and about 40% from Thai customers, because service rates for foreign customers are about 15-20% higher. It is also looking for opportunities to expand into the Bangladesh and Indonesia markets in the future. In addition, SAFE aims to expand its family care base from 40,000 families to 50,000 families within the next 3-5 years, while driving average revenue growth of 10-15% per year through its Preserve and Prevent market growth strategies and by expanding its foreign patient base, which currently accounts for as much as 50% of all patients. Over the longer term, in the next 5-10 years, SAFE's goal is to push Thailand to become a Regional Fertility Hub that families across the region trust.

Illumina shares jumped 7.7% in the afternoon session after Wall Street analysts raised their price targets on the genomics company, citing expected improvement in clinical sales and new catalysts. Analysts also pointed to growing investor interest in gene-sequencing technology as foundational infrastructure for artificial intelligence applications, according to TipRanks. The stock closed the day at $293.84, up 7.6% from the previous close, and has now gained 119% since the beginning of the year, setting a new 52-week high. The move was notable but not extreme for Illumina, which has seen 17 swings greater than 5% over the past year. The largest of those came 11 months ago, when the stock gained 22.4% after the company reported third-quarter 2025 results that beat profit expectations and raised its full-year guidance.

Alamar Biosciences has appointed Bob Ragusa, former chief executive officer of GRAIL and former chief operations officer of Illumina, to its board of directors. The Fremont, California-based precision proteomics company, which trades on Nasdaq under the ticker ALMR, also added two executives to its leadership team: John Brottem as general counsel and Amelia Merrill as chief people officer. Brottem previously served as general counsel of Outset Medical and held senior legal positions at Omnicell, while Merrill has held senior people roles at Guardant Health, RMS, Outset Medical, VeriSign, webMethods and Juniper Networks. Founder, chief executive officer and chair Yuling Luo said Ragusa helped build Illumina into the global standard for genomics and led GRAIL as it brought multi-cancer early detection to patients, and that his perspective will be invaluable as Alamar advances its mission to enable the earliest detection of disease. Alamar describes itself as a commercial-stage proteomics company built on its proprietary NULISA technology and ARGO HT System, designed to detect protein biomarkers at extremely low concentrations in blood.

EpiSign Inc. and Geneyx Genomex Ltd. announced a partnership to advance the integration of genomic and epigenomic analysis for rare-disease interpretation. Under the collaboration, EpiSign METRIC becomes available to Geneyx customers, letting laboratories incorporate epigenomic evidence alongside genomic and phenotypic information in an integrated interpretation workflow. EpiSign METRIC automates analysis of disease-associated DNA methylation episignatures across more than 300 EpiSign-associated conditions, while EpiSign METRIC 5-base extends that capability beyond methylation microarrays to methylation data generated by Illumina 5-base, PacBio HiFi and Oxford Nanopore sequencing. Geneyx Chief Executive Officer David Yizhar said the partnership combines Geneyx's genomic and multi-omics analysis platform with EpiSign's expertise in DNA methylation and episignatures, and EpiSign co-founder and Chief Scientific Officer Dr. Bekim Sadikovic said genome sequencing increasingly generates genetic and epigenetic information from the same assay. EpiSign Chief Executive Officer Dan Sinai said generating genomic and epigenomic information together from a single assay can reduce wet-lab testing and data-generation costs and shorten the diagnostic odyssey for patients and families. EpiSign METRIC 5-base is available for research use only.

CellCarta has established a strategic partnership with Waters Corporation to jointly pursue companion diagnostic and next-generation flow cytometry opportunities with pharmaceutical and biotechnology companies. The collaboration will initially emphasize flow cytometry-based programs, aiming to give sponsors a coordinated path from biomarker strategy through clinical development, regulatory submission and global commercialization. Waters will provide underlying technology capabilities including instrumentation, reagents, standardized panels, assay development, software analysis, and where appropriate custom reagent and IVD commercialization, while CellCarta will integrate and deploy assays across its global CDx Lab Network, supporting Phase I-III clinical trial testing, analytical and clinical evidence generation, regulatory and logistics support, and commercial laboratory services. The companies cited existing platform alignment between CellCarta's CAP-accredited laboratory in Jining, China and BD flow cytometry platforms as a practical foundation for global sponsors seeking to include China in future multinational CDx and biomarker programs. Todd Chermak, President of CellCarta, said the partnership offers sponsors a more connected path from biomarker strategy through global clinical development and, where appropriate, commercialization, and that the companies are already engaging pharmaceutical and biotechnology companies on near-term opportunities.

Alliance Foundation Trials and Natera announced the launch of AFT-70 NAVIGATE, a global randomized phase III trial evaluating an MRD-guided treatment strategy for patients with intermediate and high-risk ER-positive/HER2-negative early breast cancer. The trial is sponsored and led by AFT, with collaboration and co-funding from Natera and Genentech, a member of the Roche Group. It pairs giredestrant, Genentech's investigational next-generation oral selective estrogen receptor degrader, with longitudinal Signatera Genome MRD monitoring to identify patients who may benefit from escalation with a CDK4/6 inhibitor. AFT expects to enroll more than 2,000 patients with stage II-III disease at approximately 200 sites across the U.S. and internationally, with the primary endpoint of non-inferiority in 4-year distant recurrence-free survival. Giredestrant was selected based on the phase III lidERA trial, which showed a statistically significant and clinically meaningful improvement in invasive disease-free survival versus standard endocrine monotherapy, while Signatera was chosen for its evidence in this setting and its Genome-based technology reporting analytical sensitivity below 1 ppm.

Safe Fertility Group Public Company Limited, or SAFE, has announced a three-to-five-year plan to expand its family care base from 40,000 families to 50,000 families, while driving average revenue growth of 10-15% per year from 2027 onward, after revenue in 2026 is expected to hold steady from the 900 million baht recorded in 2025. Dr. Wiwat Kwangkananurak, Chief Executive Officer, said the growth strategy comes from the Preserve and Prevent markets, as younger generations increasingly turn to egg freezing, sperm freezing, and genetic testing, as well as from expanding the base of international patients, who currently account for 50% of all patients. The company is also broadening its business scope into genetic analysis laboratories under Next Generation Genomic Company Limited, providing reproductive medicine and maternal and child medicine analysis services to leading public and private healthcare providers, as well as obstetrics and gynecology clinics both domestically and overseas. It is also in discussions on cooperation with the National Health Security Office, or NHSO, on a project to screen for fetal chromosomal abnormalities from maternal blood, known as NIPT, with services under the NHSO project expected to begin in 2027. It is also discussing ways to provide intrauterine insemination, or IUI, for holders of universal health coverage rights, or the 30-baht scheme, to broaden access to treatment more comprehensively.

Jim Cramer said GRAIL, Inc. could climb much higher after an FDA advisory panel backed its Galleri multi-cancer early detection test, comparing the stock to Moderna when it traded around $120. The panel voted 7-2 with one abstention that Galleri's benefits outweighed its risks, 6-4 on effectiveness and unanimously on safety, though the recommendation is not binding and final approval had not been granted as of October 2, with Reuters reporting a decision is expected in the coming months. GRAIL generated $44.7 million of revenue in the second quarter, up 26% year over year, as Galleri revenue rose 24% to $42.6 million and test volume increased 35% to more than 61,000, while the company posted a $110.2 million net loss and a $90.3 million adjusted EBITDA loss with $861.6 million in cash, cash equivalents and short-term marketable securities at June 30. Moderna, Inc. reported $145 million of revenue in the second quarter against $142 million a year earlier and a $782 million net loss, ending June with $6.9 billion in cash, cash equivalents and investments, and its Phase 3 INTerpath-001 trial of intismeran autogene with Merck's Keytruda met its recurrence-free-survival and distant-metastasis-free-survival endpoints in resected melanoma. Citi analyst Geoff Meacham said on September 30 that Moderna's roughly $80 billion market capitalization was approaching Regeneron's despite materially lower expected revenue and earnings, while GRAIL's bear case rests on adoption and reimbursement, with Galleri costing about $700 out of pocket and generally not covered by Medicare or private insurers.

GRAIL announced in September 2026 that its Galleri multi-cancer early detection blood test showed strong performance in the PATHFINDER 2 study and received a favorable U.S. FDA advisory committee vote supporting its safety, benefit-risk profile and effectiveness for use alongside standard screening in adults aged 50 and older. The PATHFINDER 2 data indicated that adding Galleri increased cancers detected through screening more than six-fold with a very low false-positive rate, while the test also accurately pointed doctors to the likely cancer origin in over nine out of ten positive cases. The advisory committee's favorable vote and the PATHFINDER 2 results reinforce the core near-term catalyst around potential PMA approval and payer coverage, though GRAIL's high cash burn and lack of profitability remain the biggest risk. GRAIL's narrative projects $348.4 million revenue and $60.1 million earnings by 2029, with a $97.40 fair value implying a 32% downside to its current price, while some of the lowest estimate analysts were assuming only about US$277.6 million of revenue and a small US$49.4 million profit by 2029.

Dexcom released its 2026 "State of Type 2 Report: Global Access and Attitudes to Diabetes Technology" ahead of the 62nd Annual Meeting of the European Association for the Study of Diabetes, highlighting gaps in continuous glucose monitoring awareness and access while pointing to growing potential for combining CGM with GLP-1 therapies. The survey of more than 800 healthcare professionals and 2,500 people with Type 2 diabetes across eight countries found that 89% of HCPs believe CGM helps assess treatment adherence between appointments, yet 55% of surveyed Type 2 patients reported limited knowledge of the technology, and reimbursement and coverage challenges were cited by 90% of U.S. HCPs and 53% of HCPs in the other seven countries surveyed. Among existing users, 94% said CGM helps them manage diabetes more independently and 91% use CGM data to guide treatment decisions. The report also flagged an emerging intersection between CGM and GLP-1 therapies, with 58% of Type 2 patients taking GLP-1 medicines using CGM alongside their medication versus only 27% of Type 2 patients not using insulin, while half of HCPs expect increasing GLP-1 use to drive CGM adoption. Dexcom also partnered with Team Novo Nordisk, an all-diabetic professional cycling team principally sponsored by Novo Nordisk, to extend its visibility within the Type 1 diabetes community and create opportunities for real-world research, education and awareness.